{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021215","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.358742+00:00","generated_at":"2026-06-15T04:26:41.186027+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Equillium Q1 net loss narrows to $3.9M; cash $62M funds into 2025; Ono partnership revenue $8.9M","bullets":["Net loss of $3.9M ($0.11 per share) vs $37.4M loss in Q1 2022; decrease due to Ono revenue and no Bioniz acquisition costs.","Cash, cash equivalents and short-term investments $62.0M as of March 31, 2023, expected to fund operations into 2025.","Revenue of $8.9M from itolizumab development funding and amortization of upfront from Ono partnership.","Clinical milestones: EQ101 Phase 2 alopecia areata initial data 2H 2023; itolizumab EQUALISE lupus nephritis topline data 1H 2024; EQUATOR aGVHD interim review 2024.","Ono option exercise payment of ~$37M (5 billion yen) if exercised, would significantly extend cash runway."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021215","json":"https://secwatch.observer/filing/0000950170-23-021215.json","markdown":"https://secwatch.observer/filing/0000950170-23-021215.md","text":"https://secwatch.observer/filing/0000950170-23-021215.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000095017023021215/0000950170-23-021215-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000095017023021215/eq-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:26:41.186027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"308fb69e5417b8d1b088a4d358e8c27b15a6d4ae","claim":"Equillium, Inc. reported the first quarter ended March 31, 2023 results: revenue $8.9 million, net income $3.9 million, EPS $(0.11) per basic and diluted share.","evidence_excerpt":"nephritis topline data anticipated in 1H 2024, EQUATOR aGVHD interim review anticipated in 2024 First Quarter 2023 Financial Results Revenue for the first quarter of 2023 was $8.9 million and was derived from itolizumab development funding from Ono Pharmaceutical Co, Ltd. (Ono) and amortization of the upfront payment from Ono. Research and development (R&D)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746466/000095017023021215/0000950170-23-021215-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$8.9 million"},{"label":"Net income","value":"$3.9 million"},{"label":"EPS","value":"$(0.11) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}